Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Treasury Shares (2018 - 2025)

Historic Treasury Shares for Bicycle Therapeutics (BCYC) over the last 5 years, with Q3 2025 value amounting to $1.7 million.

  • Bicycle Therapeutics' Treasury Shares rose 11829.76% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 11829.76%. This contributed to the annual value of $674262.0 for FY2024, which is 10629.22% up from last year.
  • Bicycle Therapeutics' Treasury Shares amounted to $1.7 million in Q3 2025, which was up 11829.76% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Treasury Shares registered a high of $1.9 million during Q1 2025, and its lowest value of $187725.0 during Q1 2022.
  • Over the past 4 years, Bicycle Therapeutics' median Treasury Shares value was $452576.0 (recorded in 2023), while the average stood at $721910.7.
  • Over the last 5 years, Bicycle Therapeutics' Treasury Shares had its largest YoY gain of 14108.46% in 2023, and its largest YoY loss of 7411.0% in 2023.
  • Quarter analysis of 4 years shows Bicycle Therapeutics' Treasury Shares stood at $187725.0 in 2022, then surged by 74.11% to $326848.0 in 2023, then skyrocketed by 106.29% to $674262.0 in 2024, then skyrocketed by 152.83% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $1.8 million for Q2 2025, and $1.9 million during Q1 2025.